Doravirine/lamivudine/tenofovir
| Combination of | |
|---|---|
| Doravirine | non-nucleoside reverse transcriptase inhibitor |
| Lamivudine | nucleoside reverse transcriptase inhibitor |
| Tenofovir disoproxil fumarate | nucleotide reverse transcriptase inhibitor tenofovir disoproxil fumarate |
| Clinical data | |
| Trade names | Delstrigo |
| Other names | MK-1439A |
| Legal status | |
| Legal status | |
Doravirine/lamivudine/tenofovir disoproxil fumarate (brand name Delstrigo) is a fixed-dose combination drug for the treatment of HIV/AIDS.[2] It contains doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg).[3] In the United States, it was approved by the Food and Drug Administration in August 2018 for the treatment of HIV-1 infection.[3]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ "Doravirine/lamivudine/tenofovir disoproxil fumarate - Merck & Co". Adis Insight.
- ^ a b "FDA Approves Merck's DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients" (Press release). Merck & Co. August 30, 2018.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |